SOURCE: StockCall

StockCall

August 19, 2010 09:55 ET

Opinions on Gilead Sciences and Incyte - Biotech Plays Losing a Little of Their Attraction

JOHANNESBURG, SOUTH AFRICA--(Marketwire - August 19, 2010) -  www.stockcall.com/ offers investors comprehensive research on the biotechnology industry and has completed analytical research on Gilead Sciences Inc. (NASDAQ: GILD) and Incyte Corporation (NASDAQ: INCY). Register with us today at www.stockcall.com/ to have free access to these researches. 

The uncertainty surrounding heath care reform in the US has kept many investors away from the biotechnology industry. That coupled with the rise of generic alternatives in the US and Europe has prevented some biotechnology companies from making large gains. With all of that being said, innovation, product development and implementation reign paramount to a biotech company's success. Register now at https://stockcall.com/development/stockcall/page.php?name=register.html to have free access to our reports on the biotechnology industry.

www.stockcall.com/ is an online platform where investors doing their due-diligence on the biotechnology industry can have easy and free access to our analyst research and opinions on Gilead Sciences Inc. and Incyte Corporation; all investors need to do is register for a complimentary membership at https://stockcall.com/development/stockcall/page.php?name=register.html.

Recent advancements in drugs that are designed to treat prostate cancer, hepatitis C and HIV have boosted some companies' sales and in some cases profits higher. Anti-HIV drug maker Gilead Sciences Inc. reported in its July-released financial report that the company's net income was boosted 25% higher on the back of sales of its antiviral drugs. Investors looking for free research on Gilead Sciences Inc. are welcome to sign up at www.stockcall.com/GILD190810.pdf.

Advances in arthritis treatment are also looking financially promising for some biotech companies like Incyte Corporation. Investors looking for free research on Incyte Corporation are welcome to sign up at www.stockcall.com/INCY190810.pdf.

While there are some success stories in the industry, a number of players are having trouble dealing with the volatile nature of biotechnologies. Research and development costs are extremely high, and the success of a product can sometimes not be measured until late in development. That coupled with new regulations that are still unclear could prove challenging to the industry. Visit www.stockcall.com/ to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information